EP Patent

EP4248971A2 — Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization

Assigned to ADS Therapeutics LLC · Expires 2023-09-27 · 3y expired

What this patent protects

Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

USPTO Abstract

Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

Drugs covered by this patent

benoxinate-hydrochloride (BENOXINATE HYDROCHLORIDE)

Patent Metadata

Patent number: EP4248971A2
Jurisdiction: EP
Classification: —
Expires: 2023-09-27
Drug substance claim: No
Drug product claim: No
Assignee: ADS Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.